Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lonafarnib in cancer therapy.
Morgillo F, Lee HY. Morgillo F, et al. Expert Opin Investig Drugs. 2006 Jun;15(6):709-19. doi: 10.1517/13543784.15.6.709. Expert Opin Investig Drugs. 2006. PMID: 16732721 Review.
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F. Cascone T, et al. Among authors: morgillo f. J Cell Physiol. 2008 Sep;216(3):698-707. doi: 10.1002/jcp.21444. J Cell Physiol. 2008. PMID: 18381602
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
Belli V, Matrone N, Napolitano S, Migliardi G, Cottino F, Bertotti A, Trusolino L, Martinelli E, Morgillo F, Ciardiello D, De Falco V, Giunta EF, Bracale U, Ciardiello F, Troiani T. Belli V, et al. Among authors: morgillo f. J Exp Clin Cancer Res. 2019 Jun 4;38(1):236. doi: 10.1186/s13046-019-1230-z. J Exp Clin Cancer Res. 2019. PMID: 31164152 Free PMC article.
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
Della Corte CM, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Tuccillo C, Troiani T, Martinelli E, Wang J, Byers L, Morgillo F, Ciardiello F. Della Corte CM, et al. Among authors: morgillo f. J Exp Clin Cancer Res. 2022 Mar 26;41(1):109. doi: 10.1186/s13046-022-02332-2. J Exp Clin Cancer Res. 2022. PMID: 35346313 Free PMC article.
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F. Martinelli E, et al. Among authors: morgillo f. Clin Cancer Res. 2010 Oct 15;16(20):4990-5001. doi: 10.1158/1078-0432.CCR-10-0923. Epub 2010 Sep 1. Clin Cancer Res. 2010. PMID: 20810384 Free article.
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Gridelli C, et al. Among authors: morgillo f. Clin Lung Cancer. 2014 May;15(3):173-81. doi: 10.1016/j.cllc.2013.12.002. Epub 2013 Dec 27. Clin Lung Cancer. 2014. PMID: 24486058 Review.
168 results